Erratum: The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO) (Diabetes and Vascular Disease Research (2013) 10:1 (93-96)(DOI: 10.1177/1479164112444640));The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO)

Diabetes and Vascular Disease Research

Volumn 10, Issue 1, 2013, Pages 93-96

  Murakami, Kazutoshi ^a   Wada, Jun ^a   Ogawa, Daisuke ^a   Horiguchi, Chikage Sato ^a   Miyoshi, Tomoko ^a   Sasaki, Motofumi ^a   Uchida, Haruhito A ^a   Nakamura, Yoshio ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Metabolic syndrome; PPAR ; telmisartan; valsartan; visceral adipose tissue

Indexed keywords

GLUCOSE; TELMISARTAN; VALSARTAN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MALE; METABOLIC SYNDROME X; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE;

EID: 84871849211     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113507658     Document Type: Erratum

References (20)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 ; 112: 2735-2752 (Pubitemid 41532612)
2. Balkau B, Vernay M, Mhamdi L, et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. Diabetes Metab. 2003 ; 29: 526-532 (Pubitemid 37474265)
3. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003 ; 26: 575-581 (Pubitemid 36929310)
4. Lieberman LS. Dietary, evolutionary, and modernizing influences on the prevalence of type 2 diabetes. Annu Rev Nutr. 2003 ; 23: 345-377 (Pubitemid 37059728)
5. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004 ; 43: 993-1002 (Pubitemid 38579904)
6. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004 ; 109: 2054-2057 (Pubitemid 38620211)
7. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004 ; 22: 2253-2261 (Pubitemid 39625096)
8. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes. 2005 ; 54: 3442-3452 (Pubitemid 43334334)
9. Araki K, Masaki T, Katsuragi I, et al. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension. 2006 ; 48: 51-57 (Pubitemid 44297524)
10. Sugimoto K, Kazdova L, Qi NR, et al. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J Hypertens. 2008 ; 26: 1209-1215 (Pubitemid 351670512)
11. Foryst-Ludwig A, Hartge M, Clemenz M, et al. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol. 2010 ; 9:
12. Fujisaka S, Usui I, Kanatani Y, et al. Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. Endocrinology. 2011 ; 152: 1789-1799
13. Kudo H, Yata Y, Takahara T, et al. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int. 2009 ; 29: 988-996
14. Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens. 2007 ; 20: 431-436 (Pubitemid 46441748)
15. Sugimoto K, Qi NR, Kazdova L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. 2006 ; 47: 1003-1009 (Pubitemid 44297575)
16. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007 ; 25: 841-848 (Pubitemid 46398879)
17. Chujo D, Yagi K, Asano A, et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res. 2007 ; 30: 1205-1210 (Pubitemid 351176418)
18. Huang GZ, Tang YH, Wang BY, et al. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J. 2011 ; 32: 1017-1021
19. Lim SY, Kim SW, Kim EJ, et al. Telmisartan versus valsartan in patients with hypertension: effects on cardiovascular, metabolic, and inflammatory parameters. Korean Circ J. 2011 ; 41: 583-589
20. Kajiya T, Ho C, Wang J, Vilardi R, et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 2011 ; 29: 2476-2483